DK0495187T3 - Protein-nanomatricer og fremstillingsmetode. - Google Patents

Protein-nanomatricer og fremstillingsmetode.

Info

Publication number
DK0495187T3
DK0495187T3 DK91120485.7T DK91120485T DK0495187T3 DK 0495187 T3 DK0495187 T3 DK 0495187T3 DK 91120485 T DK91120485 T DK 91120485T DK 0495187 T3 DK0495187 T3 DK 0495187T3
Authority
DK
Denmark
Prior art keywords
protein
nanomatrixes
ingredient
present
reversible
Prior art date
Application number
DK91120485.7T
Other languages
English (en)
Inventor
Richard C K Yen
Original Assignee
Hemosphere Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemosphere Inc filed Critical Hemosphere Inc
Application granted granted Critical
Publication of DK0495187T3 publication Critical patent/DK0495187T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1658—Proteins, e.g. albumin, gelatin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S516/00—Colloid systems and wetting agents; subcombinations thereof; processes of
    • Y10S516/922—Colloid systems having specified particle size, range, or distribution, e.g. bimodal particle distribution
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Optics & Photonics (AREA)
  • Medical Informatics (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK91120485.7T 1991-01-15 1991-11-29 Protein-nanomatricer og fremstillingsmetode. DK0495187T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US64172091A 1991-01-15 1991-01-15

Publications (1)

Publication Number Publication Date
DK0495187T3 true DK0495187T3 (da) 1997-08-11

Family

ID=24573583

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91120485.7T DK0495187T3 (da) 1991-01-15 1991-11-29 Protein-nanomatricer og fremstillingsmetode.

Country Status (7)

Country Link
US (1) US5308620A (da)
EP (1) EP0495187B1 (da)
AT (1) ATE147976T1 (da)
DE (1) DE69124357T2 (da)
DK (1) DK0495187T3 (da)
ES (1) ES2097783T3 (da)
GR (1) GR3022703T3 (da)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616311A (en) * 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
US5725804A (en) * 1991-01-15 1998-03-10 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5783214A (en) * 1994-06-13 1998-07-21 Buford Biomedical, Inc. Bio-erodible matrix for the controlled release of medicinals
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US6861053B1 (en) 1999-08-11 2005-03-01 Cedars-Sinai Medical Center Methods of diagnosing or treating irritable bowel syndrome and other disorders caused by small intestinal bacterial overgrowth
US7048906B2 (en) * 1995-05-17 2006-05-23 Cedars-Sinai Medical Center Methods of diagnosing and treating small intestinal bacterial overgrowth (SIBO) and SIBO-related conditions
US5716643A (en) * 1995-06-07 1998-02-10 Hemosphere Inc. Large scale production of medicine coated crosslinked protein microspheres
EP1683517A1 (en) 1996-08-19 2006-07-26 American Bioscience, Inc. Methods for the production of protein particles useful for delivery of pharmacological agents
US8137684B2 (en) 1996-10-01 2012-03-20 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US5977313A (en) * 1996-10-10 1999-11-02 Quadrant Healthcare Limited Platelet substitutes and conjugation methods suitable for their preparation
WO1998047492A1 (en) * 1997-04-18 1998-10-29 Vertex Pharmaceuticals Incorporated Nanosized aspartyl protease inhibitors
CA2294494A1 (en) 1997-06-05 1998-12-10 Richard C. K. Yen Fibrinogen-coated microspheres
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
CN100462066C (zh) * 1997-06-27 2009-02-18 美国生物科学有限公司 药剂的新制剂及其制备和应用方法
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
ATE239447T1 (de) * 1997-09-29 2003-05-15 Inhale Therapeutic Syst In verneblern verwendbare, stabilisierte zubereitungen
US20020017295A1 (en) * 2000-07-07 2002-02-14 Weers Jeffry G. Phospholipid-based powders for inhalation
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US6433040B1 (en) 1997-09-29 2002-08-13 Inhale Therapeutic Systems, Inc. Stabilized bioactive preparations and methods of use
WO1999016420A1 (en) * 1997-09-29 1999-04-08 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in nebulizers
US6946117B1 (en) 1997-09-29 2005-09-20 Nektar Therapeutics Stabilized preparations for use in nebulizers
IN187039B (da) * 1997-12-08 2001-12-29 Council Scient Ind Res
WO2000000215A1 (en) * 1998-06-29 2000-01-06 Inhale Therapeutic Systems, Inc. Particulate delivery systems and methods of use
US6630169B1 (en) 1999-03-31 2003-10-07 Nektar Therapeutics Particulate delivery systems and methods of use
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
EP1280520B2 (en) 2000-05-10 2018-03-21 Novartis AG Phospholipid-based powders for drug delivery
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
US6605311B2 (en) * 2000-06-22 2003-08-12 The Procter & Gamble Company Insoluble protein particles
US7141236B2 (en) * 2000-07-28 2006-11-28 Nektar Therapeutics Methods and compositions for delivering macromolecules to or via the respiratory tract
TWI324518B (en) 2001-12-19 2010-05-11 Nektar Therapeutics Pulmonary delivery of aminoglycosides
US7186692B2 (en) * 2002-12-17 2007-03-06 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
JP2006516262A (ja) * 2002-12-17 2006-06-29 ナステック・ファーマシューティカル・カンパニー・インコーポレーテッド Ｙ２受容体結合ペプチドの粘膜送達促進のための組成物および方法ならびに肥満症の治療法および予防法
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US7229966B2 (en) * 2002-12-17 2007-06-12 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of Y2 receptor-binding peptides and methods for treating and preventing obesity
DK1592416T3 (da) * 2003-02-07 2009-04-20 Prometic Biosciences Inc Fedtsyrer med middel kædelængde, glycerider og analoger som stimulatorer af erythropoiesis
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE372421B (da) * 1968-04-01 1974-12-23 Minnesota Mining & Mfg
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
DK143689C (da) 1975-03-20 1982-03-15 J Kreuter Fremgangsmaade til fremstilling af en adsorberet vaccine
US4447355A (en) * 1982-04-07 1984-05-08 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing a tumor necrosis factor and a stable aqueous solution or powder containing the same
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
FR2608942B1 (fr) * 1986-12-31 1991-01-11 Centre Nat Rech Scient Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules

Also Published As

Publication number Publication date
ES2097783T3 (es) 1997-04-16
ATE147976T1 (de) 1997-02-15
DE69124357T2 (de) 1997-07-10
US5308620A (en) 1994-05-03
DE69124357D1 (de) 1997-03-06
GR3022703T3 (en) 1997-05-31
EP0495187B1 (en) 1997-01-22
EP0495187A1 (en) 1992-07-22

Similar Documents

Publication Publication Date Title
DK0495187T3 (da) Protein-nanomatricer og fremstillingsmetode.
FI102036B1 (fi) Menetelmä rasvaliukoisten aineiden stabiilien valmisteiden valmistamiseksi
DE59001544D1 (de) Mittel zur behandlung von schweren schmerzzustaenden und verfahren zu ihrer herstellung.
DE59607548D1 (de) Verfahren zur herstellung von morphologisch einheitlichen mikrokapseln sowie nach diesem verfahren hergestellte mikrokapseln
HUT54885A (en) Process for producing liofilized pharmaceutical compositions containing active components
ATE15141T1 (de) Verfahren zur herstellung von liposomalen arzneimitteln.
NO20003471D0 (no) Fremstilling av en lipidblanding og en fosfolipidsuspensjon som inneholder lipidblandingen
SE8403487D0 (sv) Farmaceutisk komposition
GB2297907A (en) Liposomes containing particulate materials
DE69032455D1 (de) Ophthalmische zusammensetzungen und verfahren zu ihrer konservierung und anwendung
DE69020797D1 (de) Lösung von hochmolekularen Polycarbodiimiden sowie Verfahren zu deren Herstellung.
DE3481997D1 (de) Verfahren zur herstellung optisch aktiver aryloxypropionsaeuren und deren als herbizide verwendbare derivate.
DE68927669D1 (de) Verfahren zur herstellung von in lösungsmitteln verdünnbaren mikroträgern
CA2407684A1 (en) Hematology blood control and method for preparation of same
ES2157886T3 (es) Composiciones tensioactivas y procedimientos.
ATE110527T1 (de) Schäumende wässerige zusammensetzung und verfahren zur homogenen einführung von wasser in eine lipophile phase.
ATE92075T1 (de) Verfahren zur gewinnung aktiver proteine aus einer biologisch inaktiven form.
DE69129747D1 (de) In lösung bringen von proteinen in aktiver form
KR910021361A (ko) 항궤양 물질
FI95778C (fi) Menetelmä taudinaiheuttajien inaktivoimiseksi biologisessa tai farmaseuttisessa aineessa
DK0488142T3 (da) Fremgangsmåde til indkapsling af faste eller flydende, lipofile virksomme stoffer i phospholipid-liposomer samt lægemidler indeholdende disse liposomer
SE9801705D0 (sv) Biologically active composition
ATE128176T1 (de) Verfahren zur antimikrobiellen konservierung von tensiden.
ATE96286T1 (de) Verfahren zur entfernung von cholesterin aus eigelb.
NO920524L (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse